Celcuity Inc.

CELCSEC EDGAR

Services-Medical Laboratories(DE)CIK: 1603454

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$60.6M	$35.3M	$25.8M	$7.7M	$6.3M
Operating Expenses	$66.2M	$39.4M	$28.4M	$9.6M	$7.8M
Operating Income (Loss)	-$66.2M	-$39.4M	-$28.4M	-$9.6M	-$7.8M
Interest Expense	—	$2.1M	$1.3M	$120.00	$159.00
Nonoperating Income (Expense)	$2.5M	—	—	—	$445.9K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$63.8M	-$40.4M	-$29.6M	-$9.5M	-$7.4M
Income Tax Expense (Benefit)	—	—	—	—	$0.00
Net Income (Loss) Attributable to Parent	-$63.8M	-$40.4M	-$29.6M	-$9.5M	-$7.4M
Earnings Per Share, Basic	-$2.69	-$2.64	-$2.21	—	—
Earnings Per Share, Diluted	-$2.69	-$2.64	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$191.2M	$175.7M	$85.9M	$13.0M	$20.3M
Assets, Current	$190.6M	$175.2M	$85.4M	$12.2M	$19.3M
Cash and Cash Equivalents, at Carrying Value	$30.7M	$24.6M	$84.3M	$11.6M	$15.9M
Liabilities	$51.5M	$41.9M	$17.2M	$1.3M	$983.2K
Liabilities, Current	$14.2M	$6.9M	$2.5M	$1.2M	$911.3K
Long-term Debt	$105.1M	$37.6M	$35.8M	$16.0M	—
Accounts Payable, Current	$5.1M	$2.6M	$1.5M	$217.4K	$142.8K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$53.8M	-$36.0M	-$20.3M	-$7.1M	-$6.0M
Net Cash Provided by (Used in) Investing Activities	-$5.0M	-$144.0M	-$81.4K	-$89.4K	$8.5M
Net Cash Provided by (Used in) Financing Activities	$64.9M	$120.3M	$93.0M	$138.0K	$259.3K
Payments to Acquire Property, Plant, and Equipment	$97.6K	$158.8K	$81.9K	$89.4K	-$380.2K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)